1. Introduction

Bring-Your-Own-Device (BYOD) trials are clinical research studies in which participants use their own smartphones, smartwatches, tablets, wearable sensors, or other personal electronic devices to perform study-related activities. These activities may include reporting symptoms, completing electronic questionnaires, transmitting health data, attending remote consultations, or monitoring treatment outcomes.

BYOD trials can make clinical research more convenient, reduce travel, and improve participation among people who cannot easily attend research centres. However, they also create a significant legal and ethical concern: participants who lack compatible devices, reliable internet access, digital literacy, or accessible technology may be excluded from research or disadvantaged within it.

This issue intersects with clinical-trial ethics, informed consent, equality and disability law, privacy and data protection, medical-device regulation, and the reliability of clinical evidence.

An important qualification is that BYOD trials and unequal access do not constitute one universally recognised legal doctrine. The applicable obligations depend on the jurisdiction, the nature of the research, the sponsor, the device's intended use, and whether the study is publicly funded or commercially sponsored.

2. Meaning and legal nature of BYOD trials

BYOD trials form part of the broader category of decentralised clinical trials, in which some or all research activities occur outside traditional clinical-research sites.

Strategies to Support Older Adults in Clinical Trials

A. Smartphone-based trials

Participants use their own phones to complete questionnaires, report adverse events, record medication adherence, or access study applications.

bioaccess® | MedTech, Biopharma & Radiopharma CRO in Latin America

B. Wearable-device trials

Personal watches or fitness trackers collect activity, heart rate, sleep, or other physiological measurements, where appropriate to the study.

Telemedicine Services | Kirkwood Medical Practice

C. Remote and hybrid trials

Participants use their devices for video visits, electronic consent, remote assessments, and communication with investigators.

The legal concern arises when personal-device ownership becomes a practical or formal condition of access to a clinical study, even though the device is not itself the treatment being investigated.

For example, a trial may advertise itself as open to all eligible adults but require an up-to-date smartphone, a specific operating system, continuous connectivity, and the ability to use an application independently. These requirements may exclude otherwise eligible participants for reasons unrelated to the scientific question being studied.

3. Principal unequal-access concerns

3.1 Socioeconomic discrimination

Requiring participants to supply their own technology transfers part of the research infrastructure cost from the sponsor to the participant.

People with lower incomes may lack a compatible smartphone, sufficient mobile data, a stable internet connection, or the ability to replace a broken device. A study may therefore disproportionately recruit wealthier participants.

This can undermine the fairness of participant selection, especially when the study concerns a condition that disproportionately affects disadvantaged populations.

3.2 Disability and accessibility barriers

A BYOD application may not work adequately with screen readers, magnification, captions, alternative input methods, or cognitive accessibility features. Wearables may also be unsuitable for some physical impairments or skin sensitivities.

Where applicable disability law requires reasonable accommodation, a sponsor or institution may need to provide accessible alternatives rather than simply exclude a participant.

3.3 Age and digital literacy

Older adults and people unfamiliar with mobile applications may struggle with installation, account authentication, synchronisation, or electronic questionnaires.

Age alone does not establish an inability to participate. The legal and ethical issue is whether unnecessary technological requirements exclude otherwise eligible people without adequate support.

3.4 Geographic and connectivity inequality

Rural and remote participants may face unreliable connectivity, limited technical support, or incompatible telecommunications infrastructure. A study relying on continuous data transmission can systematically under-represent such populations.

3.5 Language and cultural barriers

Applications that support only a limited set of languages may exclude eligible participants who cannot understand consent information or complete outcome assessments accurately.

3.6 Data quality and scientific validity

Device differences can produce inconsistent measurements because of variations in sensors, software versions, sampling rates, calibration, operating systems, and battery performance.

These differences can cause missing data or measurement bias. If participants without reliable devices drop out more frequently, the final study population may no longer reflect the population the treatment is intended to benefit.

4. Applicable legal framework

4.1 United States

The principal legal and regulatory sources include:

FDA guidance on decentralised clinical trials (2024): addresses trial design, remote activities, investigator responsibilities, digital technologies, consent, and participant safety.

FDA+1

FDA guidance on digital health technologies (2023): addresses the use of digital technologies for remote data acquisition and the need for technologies to be appropriate for their intended purpose.

FDA

Common Rule, 45 C.F.R. Part 46: where applicable, establishes requirements for institutional review, informed consent, and equitable selection of research subjects.

Americans with Disabilities Act (ADA) and Section 504 of the Rehabilitation Act: may require accessible participation or reasonable accommodations where their coverage requirements are met.

HIPAA: applies to covered entities and business associates in relevant circumstances; it does not automatically cover every clinical-trial sponsor or every health application.

FDA guidance generally communicates the agency's recommendations; it should not be treated as an independent statute imposing every recommendation as a binding legal obligation.

4.2 India

In India, the analysis must consider the following sources:

Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019 (NDCTR): govern relevant clinical trials of new drugs and investigational new drugs, including ethics committee oversight, informed consent, and participant protection.

Indian Council of Medical Research (ICMR), National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017): provide an important ethical framework for research involving human participants.

Constitution of India, Article 14: guarantees equality before the law and equal protection of the laws against constitutionally impermissible state action.

Constitution of India, Article 21: protects life and personal liberty and is relevant to dignity, privacy, and bodily autonomy.

Rights of Persons with Disabilities Act, 2016: may be relevant where disability-related discrimination or accessibility duties arise.

Digital Personal Data Protection Act, 2023: its application depends on the provisions in force, applicable rules, and the processing arrangement. Health-related data should not be assumed to fall outside privacy protection merely because it is collected through a personal device.

The exact obligations depend on the trial's regulatory classification, institutional arrangements, and the provisions applicable when the research is conducted.

5. Detailed explanation with case laws

There is an important distinction between direct precedent and analogical precedent. Courts have not established a comprehensive body of reported decisions specifically addressing unequal access in BYOD clinical trials. The cases below are therefore relevant for their governing principles, rather than proof that a court has already ruled against a sponsor for requiring personal devices.

Case 1: Samira Kohli v. Dr. Prabha Manchanda

Supreme Court of India · (2008) 2 SCC 1

Facts and issue: The dispute concerned medical treatment and whether the patient's consent extended to a procedure that was performed beyond the scope of the consent given.

Legal principle: The Supreme Court emphasised the importance of valid, voluntary, and sufficiently informed consent to medical treatment. Consent to one intervention does not automatically authorise a materially different intervention.

Application to BYOD trials: Consent to participate in a clinical trial should not be treated as blanket permission for every use of a participant's personal device or personal data. Participants should receive understandable information about:

What data the application or wearable collects.

Whether the research team can access other information on the device.

Who receives the trial data and how long it is retained.

Whether data will be shared with vendors or used for additional research.

Whether a loan device or non-digital alternative is available.

Limitation: This is a medical-consent case, not a decision about smartphone ownership, digital exclusion, or clinical-trial recruitment.

Case 2: Common Cause v. Union of India

Supreme Court of India · (2018) 5 SCC 1

Facts and issue: The litigation addressed end-of-life autonomy, dignity, and the legal recognition of advance directives.

Legal principle: The Court recognised the importance of autonomy and dignity as components of personal liberty under Article 21.

Application to BYOD trials: A participant's decision about whether to use a personal device, permit data collection, or continue in research should be respected within the applicable research framework. A sponsor should not make participation practically coercive by concealing alternatives or failing to explain the consequences of declining a particular technology.

Limitation: The judgment concerns end-of-life decisions, not the operation of clinical trials. Its autonomy reasoning is an analogy, not a direct BYOD holding.

Case 3: Justice K.S. Puttaswamy (Retd.) v. Union of India

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: A constitutional challenge concerning privacy led a nine-judge bench to determine whether privacy is a constitutionally protected fundamental right.

Legal principle: The Court unanimously recognised privacy as a fundamental right, linked to liberty, dignity, and autonomy.

Application to BYOD trials: Personal smartphones may contain sensitive information unrelated to the study, including communications, location history, photographs, and other application data. A trial should therefore be designed to collect only information reasonably necessary for its stated purposes, with appropriate transparency and security.

A participant's willingness to install a trial application should not be interpreted as unrestricted consent to inspect or exploit unrelated personal information.

Limitation: The judgment establishes a constitutional privacy principle; it does not itself prescribe a complete technical standard for clinical-trial applications. The precise constitutional claim also depends on the identity of the defendant and the nature of the state action.

Case 4: Alexander v. Choate

U.S. Supreme Court · 469 U.S. 287 (1985)

Facts and issue: The case concerned a reduction in the number of annual inpatient hospital days covered by Tennessee's Medicaid programme and whether that reduction violated Section 504 of the Rehabilitation Act.

Legal principle: The Court recognised the importance of meaningful access to public benefits for people with disabilities while distinguishing meaningful access from a right to obtain every benefit in an identical form.

Application to BYOD trials: Where a covered institution's research process depends on digital tools, formal permission to enrol may be insufficient if inaccessible technology prevents a person with a disability from participating meaningfully. Depending on the applicable law, the sponsor or institution may need accessible software, assistance, an alternative assessment method, or a suitable device.

Limitation: The case does not establish a general obligation for every private clinical-trial sponsor to provide every participant with a smartphone. Its application depends on the governing disability law and the institution's coverage.

Case 5: Tennessee v. Lane

U.S. Supreme Court · 541 U.S. 509 (2004)

Facts and issue: The case concerned access to state court proceedings for people with disabilities under Title II of the ADA.

Legal principle: The Court upheld Congress's authority to apply Title II to state court access in the circumstances before it, emphasising fundamental rights and the barriers people with disabilities may face when accessing public services.

Application to BYOD trials: This supports the broader proposition that a service cannot always be considered accessible merely because it is nominally open to everyone. A digital-only research process may create a substantial participation barrier for people who need an accessible interface or a different means of communication.

Limitation: Court access is distinct from research participation. The decision should be used as an analogy, and the applicability of the ADA to a particular research organisation must be separately established.

Case 6: National Federation of the Blind v. Target Corp.

U.S. District Court, Northern District of California · 452 F. Supp. 2d 946 (N.D. Cal. 2006)

Facts and issue: The litigation concerned whether barriers on Target's website could support claims under the ADA and California law.

Legal principle: At the pleading stage, the court allowed relevant claims to proceed where the website barriers were alleged to impede access to services connected with physical stores. The decision is not a universal holding that every website is covered by the ADA.

Application to BYOD trials: A research application that cannot be navigated with assistive technology may create an avoidable barrier to recruitment, consent, symptom reporting, and follow-up. This case illustrates why digital accessibility should be evaluated as part of the overall service rather than as a cosmetic software feature.

Limitation: The case involved website accessibility in a commercial setting, not clinical research. Modern accessibility disputes also depend on the particular statute, jurisdiction, and facts.

Case 7: Grimes v. Kennedy Krieger Institute, Inc.

Maryland Court of Appeals · 366 Md. 29, 782 A.2d 807 (2001)

Facts: Children from low-income families participated in research examining methods of reducing lead exposure in residential housing. The litigation alleged that the research exposed children to risks that the investigators failed adequately to prevent or disclose.

Legal principle: The court held that the research relationship and associated agreements or regulations could give rise to duties of care, and that the claims could proceed rather than being dismissed on the ground that no legal duty existed.

Justia Law+1

Application to BYOD trials: This case is particularly instructive because it concerns the interaction between socioeconomic disadvantage, human-subject research, informed consent, and the responsibilities of investigators.

A research institution should not assume that a participant's consent transfers the entire burden of safety and participation to the participant. If a study design predictably disadvantages people with limited resources, investigators should assess that problem rather than treating it as an unavoidable consequence of recruitment.

For example, if a study recruits low-income patients but requires expensive wearable technology, the sponsor should assess whether the device requirement is scientifically necessary and whether providing equipment would allow more equitable participation.

Limitation: The court did not decide a BYOD-access dispute. Its reasoning concerns research-related duties of care and alleged harm, not a freestanding right to receive a smartphone.

6. Indian legal analysis: how unequal access could create liability

In India, the legal analysis should distinguish between an ethically deficient study design and an independently actionable legal violation.

6.1 Ethics committee responsibility

Rules 15–17 of the NDCTR 2019 address ethics committees for biomedical and health research, including review and oversight under the ICMR framework. For regulated clinical trials, the applicable clinical-trial ethics committee requirements also need to be satisfied.

IndiaCode+1

An ethics committee reviewing a BYOD protocol should examine:

Whether device ownership is genuinely necessary for the research question.

Whether the proposed eligibility criteria exclude disadvantaged participants without sufficient justification.

Whether devices, connectivity, training, and technical support should be supplied.

Whether informed-consent documents explain digital-data collection and associated risks.

Whether alternative participation methods preserve scientific validity and participant safety.

A failure to consider these issues does not automatically establish civil or constitutional liability. The consequences depend on the applicable legal duties, the facts, and the nature of the resulting harm.

6.2 Informed consent and voluntariness

The NDCTR framework requires freely given, informed written consent for trials within its scope and requires participant information to be understandable.

CDSCO

For a BYOD study, meaningful disclosure should explain material technological requirements before enrolment. If a participant must pay for mobile data, use a particular operating system, or permit a specified form of data collection, those conditions should not be hidden in technical documentation.

Consent is not a substitute for fair recruitment, valid scientific design, or appropriate protection of research participants.

6.3 Equality under Articles 14 and 21

Articles 14 and 21 may be relevant where state action, public institutions, or other legally cognisable constitutional relationships are involved.

An exclusion criterion based on a device requirement is not automatically unconstitutional. A legal challenge would need to examine the justification for the requirement, its practical effects, the relevant duty of the defendant, and the remedy sought.

For instance, a publicly funded research programme that excludes eligible people solely because they cannot afford a smartphone may raise a different equality concern from a private trial that requires a particular validated sensor because its measurement is indispensable to the study.

6.4 Disability-related accommodation

Where the Rights of Persons with Disabilities Act, 2016, or another applicable law imposes accessibility or non-discrimination duties, investigators and institutions should assess reasonable accommodations.

Possible measures include accessible applications, compatible assistive technologies, supported consent, alternative assessment formats, or sponsor-provided equipment.

The precise statutory obligation depends on the relevant provisions and the organisation's legal status; not every private research sponsor is subject to identical duties.

7. When does BYOD become legally problematic?

The following scenarios illustrate the distinction between a manageable operational difficulty and a potentially serious legal or ethical concern.

These scenarios do not all establish legal violations. The relevant law, study protocol, risk, and available alternatives determine the outcome.

8. Compliance and governance framework

A well-governed BYOD trial should implement the following safeguards.

1. Equitable recruitment

Evaluate device ownership, connectivity, disability, language, age, and digital literacy in the intended study population. Do not use technology ownership as a proxy for clinical eligibility unless scientifically justified.

2. Device-provisioning policy

Supply validated loan devices, accessories, or connectivity support when needed to prevent avoidable exclusion. A mixed BYOD and sponsor-provided-device model can preserve participant choice.

3. Privacy and security

Minimise permissions, separate trial data from personal content, restrict access, establish retention rules, and document vendor responsibilities and breach-response procedures.

4. Scientific validation

Predefine compatible devices and software versions, validate measurement performance, monitor missingness, and prespecify how data from different device types will be analysed.

5. Oversight and documentation

Include access risks, accommodation procedures, contingency plans, and data-quality controls in the protocol and relevant ethics submissions. Review exclusion and dropout patterns throughout the study.

These recommendations are consistent with the practical considerations identified in published BYOD research and regulatory guidance on decentralised trials.

PMC+2

9. Burden of proof and potential remedies

Where a dispute arises, the applicable burden of proof depends on the cause of action and jurisdiction.

A claimant might need to establish some combination of:

A legal duty owed by the sponsor, investigator, institution, or technology provider.

An unjustified exclusion, breach of duty, defective consent process, or other actionable conduct.

Actual injury, loss, denial of a protected right, or another legally recognised basis for relief.

A sufficient causal connection between the alleged breach and the claimed harm.

Potential remedies, where authorised by law, may include an injunction or other corrective order, reconsideration of eligibility, provision of accessible participation methods, damages for established loss, regulatory action, or changes to the research protocol.

Not every participant who is unable to use a BYOD application will have an individual damages claim. Ethical concerns can justify preventive action even where the elements of a legal claim have not been established.

10. Conclusion

BYOD trials offer genuine advantages, but their convenience can conceal structural inequality. When participation depends on personal technology, the trial may disproportionately exclude low-income individuals, people with disabilities, rural communities, older adults, and people with limited digital literacy.

The strongest legal and ethical approach is to treat access to technology as a trial-design and participant-protection issue, not simply as an individual's responsibility.

The most relevant judicial authorities serve different purposes: Samira Kohli addresses informed consent; Puttaswamy addresses privacy and autonomy; Alexander v. Choate, Tennessee v. Lane, and National Federation of the Blind v. Target illustrate accessibility principles; and Grimes v. Kennedy Krieger Institute demonstrates the potential duties of researchers toward human subjects. None, however, establishes a universal rule that all BYOD trials must supply every participant with a device.

For Indian clinical research, the practical priority is to combine the applicable clinical-trial and ethics requirements with proportionate privacy protections, justified eligibility criteria, accessible technology, and alternatives for participants who cannot reasonably supply their own devices. That approach improves both the fairness of participation and the credibility of the resulting scientific evidence.